公开(公告)号：US11826417B2

公开(公告)日：2023-11-28

申请号：US17986424

申请日：2022-11-14

申请人： Etubics Corporation

发明人： Joseph P. Balint ,  Frank R. Jones ,  Richard B. Gayle, III

IPC分类号： A61K39/12 ,  A61K39/21 ,  C12N15/86 ,  A61K39/00 ,  A61P35/00 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/235 ,  C07K14/005 ,  C07K14/705 ,  C07K14/71

CPC分类号： A61K39/12 ,  A61K38/191 ,  A61K38/193 ,  A61K38/204 ,  A61K38/208 ,  A61K38/2013 ,  A61K38/2026 ,  A61K38/2033 ,  A61K38/2046 ,  A61K38/2066 ,  A61K38/217 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/001106 ,  A61K39/001182 ,  A61K39/21 ,  A61K39/235 ,  A61P35/00 ,  C07K14/005 ,  C07K14/70503 ,  C07K14/71 ,  C12N15/86 ,  A61K2039/5256 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/57 ,  A61K2039/575 ,  C12N2710/10034 ,  C12N2710/10321 ,  C12N2710/10334 ,  C12N2710/10343 ,  C12N2710/10371 ,  C12N2710/20034 ,  C12N2740/15034 ,  C12N2740/16234 ,  C12N2800/24

摘要： Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

公开(公告)号：US11692012B2

公开(公告)日：2023-07-04

申请号：US17214598

申请日：2021-03-26

申请人： Oregon Health & Science University

发明人： Klaus Frueh ,  Scott G. Hansen ,  Jay Nelson ,  Louis Picker ,  Patrizia Caposio

IPC分类号： C07K14/045 ,  A61K39/12 ,  C12N15/86 ,  A61K35/33 ,  A61K39/00 ,  A61K39/39 ,  C12N15/85 ,  A61K39/21 ,  C07K14/16 ,  A61P35/00

CPC分类号： C07K14/045 ,  A61K35/33 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/39 ,  C12N15/85 ,  C12N15/86 ,  A61K39/21 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/572 ,  A61P35/00 ,  C07K14/161 ,  C12N2710/16143 ,  C12N2740/15034 ,  C12N2740/16234

摘要： Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.

公开(公告)号：US20180346520A1

公开(公告)日：2018-12-06

申请号：US15573701

申请日：2016-05-13

申请人： THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND ,  UNIVERSITY OF WASHINGTON

发明人： Barbara K. Felber ,  George N. Pavlakis ,  James I. Mullins ,  Antonio Valentin ,  Siriphan Manocheewa

IPC分类号： C07K14/005 ,  A61K9/00 ,  A61K39/21 ,  A61K39/39 ,  C07K14/535

CPC分类号： C07K14/161 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/572 ,  C12N2740/16234 ,  C12N2740/16271

摘要： The invention provides methods and compositions for eliciting broad immune responses to HIV envelope proteins. The methods include use of nucleic acids constructs that encode conserved elements of HIV Env to induce immune responses.

公开(公告)号：US20180228885A1

公开(公告)日：2018-08-16

申请号：US15751640

申请日：2016-08-10

申请人： ORBIS HEALTH SOLUTIONS LLC

发明人： Thomas E. Wagner

IPC分类号： A61K39/095 ,  A61K39/12

CPC分类号： A61K39/095 ,  A61K39/12 ,  A61K2039/523 ,  A61K2039/55505 ,  A61K2039/572 ,  A61K2039/6006 ,  C12N2740/16034 ,  C12N2740/16234 ,  C12N2740/16334 ,  C12N2760/16134

摘要： The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making bacterial and viral vaccines.

公开(公告)号：US09862927B2

公开(公告)日：2018-01-09

申请号：US13011798

申请日：2011-01-21

申请人： Jacques F. Banchereau ,  Monica Montes ,  Anna Karolina Palucka ,  Louis M. Sloan ,  Yves Levy

发明人： Jacques F. Banchereau ,  Monica Montes ,  Anna Karolina Palucka ,  Louis M. Sloan ,  Yves Levy

IPC分类号： A61K39/21 ,  C12N5/0784 ,  C07K14/005 ,  A61K39/12 ,  A61K39/00

CPC分类号： C12N5/0639 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5154 ,  A61K2039/545 ,  A61K2039/6018 ,  C07K14/005 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/24 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16322 ,  C12N2740/16334

摘要： Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).

公开(公告)号：US20170196960A1

公开(公告)日：2017-07-13

申请号：US15242904

申请日：2016-08-22

申请人： GlaxoSmithKline Biologicals, S.A.

发明人： Gerald Hermann VOSS

IPC分类号： A61K39/04 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K39/015 ,  A61K39/04 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10334 ,  C12N2710/10343 ,  C12N2710/10371 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2740/16334 ,  C12N2799/022 ,  C12N2799/04 ,  Y02A50/412

摘要： The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.

公开(公告)号：US20170165321A1

公开(公告)日：2017-06-15

申请号：US15325131

申请日：2015-07-09

申请人： Bionor Immuno AS

发明人： Anker Lundemose ,  Mats Ökvist ,  Arnt Ove Hovden ,  Maja Sommerfelt Grønvold

IPC分类号： A61K38/16 ,  A61K31/4045 ,  A61K38/15

CPC分类号： A61K38/162 ,  A61K31/4045 ,  A61K31/454 ,  A61K38/12 ,  A61K38/15 ,  A61K39/12 ,  A61K39/21 ,  A61K45/06 ,  A61K2039/55522 ,  A61K2121/00 ,  A61K2300/00 ,  C12N2740/16034 ,  C12N2740/16234

摘要： The present invention relates to novel compositions of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel methods for treatment of HIV infection and prevention of AIDS.

公开(公告)号：US09670253B2

公开(公告)日：2017-06-06

申请号：US14632869

申请日：2015-02-26

申请人： Beth Israel Deaconess Medical Center, Inc. ,  Los Alamos National Security, LLC

发明人： Dan H. Barouch ,  Bette T. Korber ,  William M. Fischer

IPC分类号： A61K39/21 ,  A61K39/12 ,  A61K39/00 ,  C07K14/005 ,  A61K39/235 ,  A61K39/275 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2710/24043 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16322 ,  C12N2740/16334 ,  Y02A50/467

摘要： The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

公开(公告)号：US09630996B2

公开(公告)日：2017-04-25

申请号：US14368102

申请日：2012-12-21

申请人： THE UNIVERSITY OF WESTERN ONTARIO

发明人： Chil-Yong Kang ,  Gyoung Nyoun Kim

IPC分类号： A61K39/205 ,  A61K39/00 ,  C07K14/145 ,  C12N7/04 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/205 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N7/04 ,  C12N2740/16071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2760/20221 ,  C12N2760/20222 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20262 ,  C12N2760/20271 ,  C12N2770/24234 ,  C12N2770/24271

摘要： The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.

公开(公告)号：US09629907B2

公开(公告)日：2017-04-25

申请号：US13284824

申请日：2011-10-28

申请人： David B Weiner ,  Michele Kutzler

发明人： David B Weiner ,  Michele Kutzler

IPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/21 ,  C07K14/005 ,  A61K39/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/55516 ,  C07K14/005 ,  C12N2740/16222 ,  C12N2740/16234 ,  Y02A50/394

摘要： Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes a protein selected from the group consisting of: CTACK, TECK, MEC and functional fragments thereof are disclosed. Methods of inducing an immune response, including methods of inducing mucosal immune responses, in an individual against an immunogen, using such compositions are disclosed.